利润与现金流在接受归属人头下行风险、却缺乏单次治疗成本数据来定价合同时出现分歧。 对医疗服务提供商而言，这表现为特定情况。关键数字是单次治疗成本和 payer mix，行业特有问题是已在 38,000 人头上接受下行风险，却缺少定价所需单次治疗成本数据。这个问题的通用版本与你实际面对的版本，第一步动作不同。
利润与现金流在接受归属人头下行风险、却缺乏单次治疗成本数据来定价合同时出现分歧。 对医疗服务提供商而言，这表现为特定情况。关键数字是单次治疗成本和 payer mix，行业特有问题是已在 38,000 人头上接受下行风险，却缺少定价所需单次治疗成本数据。这个问题的通用版本与你实际面对的版本，第一步动作不同。
贡献毛利健康的提供商仍会损失现金，原因是价值导向合同下治疗完成但付款人尚未结算、面板规模扩大但单次治疗成本可见度未匹配，以及 payer mix 转向治疗后付款而非归属时点付款的合同。
因此增加归属人头会扩大而非缩小现金缺口，因为每新增一个价值导向合同下的人头，都会增加成本仅在事后才知的治疗量。
直接杠杆是针对归属人头更及时提交索赔、在价值导向合同中协商阶段性付款，以及将面板规模缩减至已有单次治疗成本数据支持定价的子集。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 提供商贡献在损益表上显示为正，而同一面板却出现现金调用。
✓ 治疗完成与付款人汇款之间的天数延长，却无任何合同变更记录。
✓ 价值导向合同下归属人头每次扩大，都与现金头寸收紧同时发生。
通常会让情况更糟的做法。 在造成缺口的单次治疗成本数据和合同条款未改变的情况下，通过借款来填补缺口。
It is for you if you run or finance a healthcare provider and the P&L looks healthy and the bank balance does not. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Turn 38,000 downside-risk lives into a self-funding 36-month analytics platform via payer co-development.
The leak it closes. Settlement lag (6–9 months) and payer audit adjustments reduced via internal attribution engine
The assumption it rests on. Payer agrees to 5-year exclusivity and 15–25% platform margin split — the engine put the probability at 0.75.
| Investment required | $2.5–3.0M over 18 months |
| Expected return | 7.6–9.1× over three years on $2.5–3.0M investment |
| Revenue, year 1 | $0 (platform build phase) |
| Revenue, year 2 | $6.9–11.4M (first shared-savings settlement) |
| Revenue, year 3 | $13.7–22.8M (full run-rate) |
| Exit criteria | Terminate if payer refuses exclusivity by Month 6 OR if attribution accuracy <80% by Month 18 OR if shared-savings pool < $60M by end of contract year 2 |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Proprietary EFF Methodology, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
因为利润在开票时确认，现金在人们付款时移动。这两者之间的差距乘以增长，就是增长消耗的现金量。
通常是开票延迟和押金，因为两者都在你控制范围内且立即生效。追讨债务人有帮助但更慢；重新谈判供应商条款有帮助但更慢。
仅在同时关闭缺口的情况下。融资结构性营运资金周期而不改变周期，意味着在下一次增长步骤时以更差条件再次借款。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית